SecBot SecBot

FEMY

FEMASYS INC
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001339005 Healthcare & Medical Devices
$1.41 −0.09 (−6.00%)
Oct 26 4:00 PM ET · prev $1.50
Market cap
$13.1M
Nano cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$10.00
+609% · range $10.00–23.00
Next earnings
Nov 12
in 16 days · EPS est. −$0.60
1 year
−90.1%
from $14.18 · Oct 27
30 days
−40.8%
from $2.38
52-week range
$1.41–20.80
at the low
Avg volume 20D
114.5K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$134.0K
5 buyers · 0 sellers · 12 mo
Filing reports
10
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 3 bearish · 1 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 5/7 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL Empery Asset Management, LP filed a Schedule 13G disclosing a 5.6% passive stake in Femasys Inc…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    5 insiders bought $134.0K at an average $3.20. No open-market sales. Price is 56% below their cost.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.500 → −$0.605 over 90 days. 2 up, 0 down in 30 days.

  • TrendDOWNTREND

    41% below its 50-day average. New closing low $1.41 on Oct 26.

Who's buying

13F
Top holderSharesValue
VANGUARD CAPITAL MANAGEMENT LLC62,232$260.1K
JANE STREET GROUP, LLC52,511$219.5K
GEODE CAPITAL MANAGEMENT, LLC30,920$129.3K
UBS Group AG18,777$78.5K
CITADEL ADVISORS LLC16,921$70.7K
VANGUARD FIDUCIARY TRUST CO12,492$52.2K
OSAIC HOLDINGS, INC.2,397$10.0K
BlackRock, Inc.1,784$7.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +609%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 18, 2026Lake Street
MAINTAIN
MAINTAINBuy
Aug 14, 2026Maxim Group
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
FEMY Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 20, 2026
Announcement
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients...
Sep 2, 2026
Reg SHO list
Reg SHO Threshold: FEMY exited the threshold list
FEMASYS INC COM NEW (DE) | On list since 2026-08-26
Aug 26, 2026
Reg SHO list
Reg SHO Threshold: FEMY entered the threshold list
FEMASYS INC COM NEW (DE) | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding
Aug 14, 2026
Earnings
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ®…
Aug 7, 2026
Offering
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ…

Insider ledger

Form 4
$134.0K
bought · 5 insiders
$0
sold · 0 insiders
−55.9%
vs their $3.20 cost
DateInsiderTypeValue
Aug 7, 2026
Lee-Sepsick Kathy
Chief Executive Officer
BUY$50.0K
Aug 7, 2026
Lee-Sepsick Kathy
Chief Executive Officer
AWARD15,625 sh
Aug 7, 2026
Lee-Sepsick Kathy
Chief Executive Officer
AWARD15,625 sh
Aug 7, 2026
Elefant Dov
Chief Financial Officer
BUY$50.0K
Aug 7, 2026
Elefant Dov
Chief Financial Officer
AWARD15,625 sh
Aug 7, 2026
Elefant Dov
Chief Financial Officer
AWARD15,625 sh
Aug 7, 2026
Canning John Charles
Chief Operating Officer
BUY$14.0K
Aug 7, 2026
Canning John Charles
Chief Operating Officer
AWARD4,375 sh

Earnings setup

Estimates
Nov 12
reports in 16 days
−$0.60
EPS estimate, this quarter
+60%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.60-$0.68–-$0.53-0.8%$619.5K
Next Q-$0.51-$0.56–-$0.46-3.0%$687.5K
Current FY-$2.60-$3.03–-$2.17-1.2%$2.1M
Next FY-$2.13-$2.59–-$1.66+0.0%$8.9M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Jul 21, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 Press
Femasys announced a partnership with SandsRx Pharmacy to support the commercial launch of its FemaSeed fertility…
Impact 3/10
Oct 20, 2026 Announcement
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
First in a planned network of specialty pharmacy partnerships provides medication coordination and p
Oct 15, 2026 SEC
Empery Asset Management, LP filed a Schedule 13G disclosing a 5.6% passive stake in Femasys Inc., representing 468,750…
SC 13G — Impact 4/10
Sep 29, 2026 SEC
Femasys Inc.'s shelf registration on Form S-3 (File No. 333-298747) became effective on September 28, 2026. This…
EFFECT — Impact 5/10
Aug 14, 2026 SEC
Femasys reported Q2 2026 revenue of $331,827 (down 18.9% YoY) and a net loss of $4,469,095 ($-1.33/share), with no…
8-K — Impact 6/10
Aug 7, 2026 Press
Femasys announced a $30 million private placement led by Nantahala Capital, selling 9.37M shares and warrants for…
Impact 7/10
Aug 7, 2026 Insider
Lee-Sepsick Kathy bought 15,625 shares
Chief Executive Officer @ $3.20 ($50.0K)
Aug 7, 2026 Insider
Lee-Sepsick Kathy was granted 15,625 shares
Chief Executive Officer

Washington

Q3 2026
Lobbying Q3 None last Q4 2024
YoY n/a vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
8 quarters Open in Washington ›

Corporate Lobbying

This company's lobbying spend, firms, issues and congressional activity are for subscribers.

Subscribe for Full Access

SecBot reports

10 filings · 2 press releases · 2 bullish · 2 bearish · 1 mixed · 5 neutral
All FEMY filing & press-release reports (12)